ArticleJournal for immunotherapy of cancer2026
Dexamethasone activates anti-tumor immunity in multiple myeloma by dismantling the GR-PPP1CB complex to restore STING/IRF3 signaling.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cyclic GMP-AMP synthase/stimulator of interferon genes (cGAS-STING) pathway mediates anti-tumor immunity by sensing cytosolic DNA and producing type I interferons, but is frequently suppressed in multiple myeloma (MM), enabling immune evasion. Dexamethasone (DXM), a cornerstone glucocorticoid in MM therapy, is paradoxically combined with immunotherapies despite its immunosuppressive reputation. The mechanisms by which DXM and its glucocorticoid receptor (GR) modulate the MM immune microenvironment remain elusive.
methodsWe analyzed the tumor immune microenvironment using single-cell RNA sequencing in 5TMM3VT murine models. STING-knockout mice were employed for genetic validation, and the PP1 inhibitor salubrinal for pharmacological studies. Protein-protein interactions were examined by co-immunoprecipitation, mass spectrometry, and immunofluorescence. NK cell cytotoxicity and macrophage polarization were assessed using co-culture systems with flow cytometry, quantitative real-time PCR, and ELISA.
resultsWe identified that GR constitutively recruits the phosphatase PPP1CB to dephosphorylate and inactivate the TBK1-IRF3 complex, thereby suppressing cGAS-STING signaling in MM cells under basal conditions. As the specific ligand of GR, DXM rapidly binds to GR, leading to the disruption of the GR-PPP1CB-TBK1-IRF3 complex, which in turn reactivates STING signaling and induces interferon-stimulated gene expression. Single-cell analysis revealed that DXM remodeled the immune microenvironment, enhancing NK cell cytotoxicity, and promoting M1-like macrophage polarization. These immunostimulatory effects were abrogated in STING-deficient models. Pharmacological inhibition of PP1 with salubrinal recapitulated DXM's effects, synergized with bortezomib to prolong survival
conclusionsThis study uncovers a glucocorticoid-sensitive inhibitory axis wherein GR-PPP1CB constitutively suppresses STING-TBK1-IRF3 signaling in MM. DXM relieves this suppression, reactivating innate anti-tumor immunity. PP1 inhibition represents a promising therapeutic strategy to enhance anti-myeloma immunity and overcome immune evasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.